$599

MannKind Receives Warning for Afrezza Facebook Promo

FDA’s Office of Prescription Drug Promotion (OPDP) issued a letter to MannKind claiming misleading/false advertising for Afrezza Facebook posts. According to the letter, on February 9 and March 19, 2018, MannKind posted advertisements on Facebook that made “false or misleading claims and/or representations about the risks associated with Afrezza by suggesting that there are no safety concerns associated with the use of the drug.” The Facebook posts have since been deleted. Below, FENIX provides thoughts on the warning letter including any potential impact to the Afrezza brand.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.